{"id":"NCT00589914","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","briefTitle":"Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia","officialTitle":"A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects With Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-03","primaryCompletion":"2009-06","completion":"2009-06","firstPosted":"2008-01-10","resultsPosted":"2011-10-04","lastUpdate":"2014-06-24"},"enrollment":1221,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"RISPERDAL CONSTA","otherNames":[]},{"type":"DRUG","name":"Paliperidone palmitate","otherNames":[]}],"arms":[{"label":"RISPERDAL CONSTA","type":"ACTIVE_COMPARATOR"},{"label":"R092670","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to demonstrate the effectiveness of paliperidone palmitate in patients with Schizophrenia.","primaryOutcome":{"measure":"Change in the Positive and Negative Syndrome Scale (PANSS) Total Score for Schizophrenia","timeFrame":"Baseline to the last postrandomization assessment in the double-blind treatment period (approximately 13 weeks)","effectByArm":[{"arm":"R092670","deltaMin":-18.6,"sd":15.45},{"arm":"RISPERDAL CONSTA","deltaMin":-17.9,"sd":14.24}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":7},"locations":{"siteCount":82,"countries":["United States","Austria","Bulgaria","Czechia","Estonia","France","Germany","Hungary","India","Lithuania","Poland","Russia","Spain","Ukraine"]},"refs":{"pmids":["24754314","24113628","23446197","21092748"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=744&filename=CR012289_CSR.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":41,"n":606},"commonTop":["Insomnia","Headache","Somnolence","Injection site pain"]}}